We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bruker and 3M Collaborate for MALDI Imaging for Cancer Research

By LabMedica International staff writers
Posted on 14 Jun 2013
Bruker Corp. More...
(Billerica, MA, USA) reported that it has signed an exclusive patent license agreement with 3M Company (Maplewood, MN, USA), which allows Bruker to include 3M patented technology related to matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging.

The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin. The technology enables researchers to study formalin-fixed, paraffin-embedded (FFPE) tissue for drug development and life-science research.

MALDI imaging has been increasingly utilized to analyze clinically pertinent tissues such as tumor biopsies. The molecular phenotypes visualized by MALDI imaging have been demonstrated to correlate with parameters such as disease status or patient outcome, and have been effectively applied to the categorization of tissue samples.

MALDI imaging was first developed for the analysis of fresh, frozen tissue sections, however, the analysis of preserved FFPE tissue sections is becoming increasingly important due to methodological enhancements. In the MALDI imaging community, it is widely accepted that a meaningful analysis of FFPE tissue requires a pretreatment called antigen-retrieval.
Dr. Sören-Oliver Deininger, market manager for MALDI imaging at Bruker, stated, “The interest in the analysis of FFPE tissue by MALDI imaging is increasing strongly. Bruker has developed innovative technology to make MALDI imaging viable in histopathology by the integration of virtual microscopy and the possibility to classify tissue based on the molecular phenotypes [class-imaging]. Our license agreement with 3M shows our ongoing commitment to the MALDI imaging field, and gives our customers the necessary freedom to conduct their research and advance the field.”

MALDI imaging is suited to analyze biomarkers in tissue samples. By enabling histologic correlation of molecular phenotypes and correlation of molecular signals to clinical endpoints, the technology is an effective application for cancer research. It directly images metabolites, peptides, proteins, lipids, and drugs in FFPE samples with no antibodies, probes, fluorescent dyes, or radiolabels needed.

However, analysis can be complex, tiresome, and difficult to interpret. Bruker has developed special software that supports the entire workflow, including statistical analysis, providing simple and automated interpretation and reporting of results. This new agreement with 3M supports the continued development and use of this important enabling application.


Related Links:

Bruker
3M Company



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Gel Cards
DG Gel Cards
New
Gold Member
Rapid AKI Test
Acute Kidney Injury (AKI) Array (4-plex)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.